Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease
FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease
FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease
Submitted by
admin
on January 14, 2019 - 10:37am
Source:
CP Wire
News Tags:
Pfizer
ATTR
transthyretin amyloid cardiomyopathy
tafamidis
Headline:
FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease
snippet:
The tafamidis meglumine form (20 mg capsule) has been granted Priority Review
Tafamidis was granted Orphan Drug Designation for ATTR-CM in both the EU and US in 2012
Do Not Allow Advertisers to Use My Personal information
